Publication | Closed Access

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

Advanced Nonsquamous NsclcMedicineWithout PembrolizumabImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentOncologyRadiation OncologyNovel TherapyKeynote-021 Cohort G